My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Kodiak Sciences Inc - Common Stock (NQ:KOD)

22.39 +0.52 (+2.35%)

Streaming Delayed Price Updated: 1:28 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kodiak Sciences Inc - Common Stock

< Previous 1 2 3 4 5 Next >

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

Analyst Ratings for Kodiak Sciences ↗

April 12, 2022

Within the last quarter, Kodiak Sciences (NASDAQ:KOD) has observed the following analyst ratings:

Via Benzinga

Recap: Kodiak Sciences Q4 Earnings ↗

March 01, 2022

Kodiak Sciences (NASDAQ:KOD) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:10 PM. Here's what investors need to know about the announcement. Earnings Kodiak...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

February 23, 2022

On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

Bonds Are Screaming “Recession.” That’s Great News For One Top Sector. ↗

March 29, 2022

The 10-2 year treasury yield spread is close to zero. Here's what you should do about this warning sign of a coming recession.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Wednesday ↗

March 02, 2022

Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...

Via Benzinga

Read Why Barclays Analyst Is 'Negatively Biased' On Kodiak Sciences ↗

February 07, 2022

Barclays has lowered the firm's price target on Kodiak Sciences Inc (NASDAQ: KOD

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 02, 2022

Gainers IsoPlexis (NASDAQ:ISO) shares moved upwards by 22.8% to $5.5 during Wednesday's pre-market session. The company's market cap stands at $214.2 million. The...

Via Benzinga

The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi ↗

March 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label...

Via Benzinga

28 Stocks Moving in Wednesday's Pre-Market Session ↗

March 02, 2022

Gainers Guardion Health Sciences, Inc. (NASDAQ: GHSI) rose 46.4% to $0.4098 in pre-market trading after jumping around 48% on Tuesday. Guardion Health Sciences recently reported...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...

Via Talk Markets

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

3 Moonshot Stocks Insiders Are Buying. What Do They Know? ↗

February 25, 2022

Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.

Via InvestorPlace

Expert Ratings For Kodiak Sciences ↗

February 24, 2022

Analysts have provided the following ratings for Kodiak Sciences (NASDAQ:KOD) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

February 24, 2022

SVB Leerink lowered Guardant Health, Inc. (NASDAQ: GH) price target from $170 to $140. Guardant Health shares dropped 5.7% to $56.22 in pre-market trading.

Via Benzinga

63 Biggest Movers From Yesterday ↗

February 24, 2022

Gainers Tenneco Inc. (NYSE: TEN) shares surged 93.9% to close at $19.35 on Wednesday after the company announced it will be acquired by Apollo Funds. Tenneco also reported a...

Via Benzinga

KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today? ↗

February 23, 2022

Disappointing drug trial results have sent Kodiak Sciences and shares of KOD stock plunging more than 80% in today's trading session.

Via InvestorPlace

Mid-Afternoon Market Update: U.S. Stocks Extend Losses; Dow Dips 300 Points ↗

February 23, 2022

U.S. stocks extended losses toward the end of trading, with the Dow Jones falling 300 points on Wednesday. US President Biden late Tuesday announced sanctions on some Russian...

Via Benzinga

Mid-Day Market Update: U.S. Stocks Turn Negative; Nasdaq Drops 50 Points ↗

February 23, 2022

U.S. stocks turned lower midway through trading after recording sharp losses on Tuesday. US President Biden late Tuesday announced sanctions on some Russian banks and individuals...

Via Benzinga

S&P 500 Slips Further into Correction Territory as Stocks Give Up Gains ↗

February 23, 2022

Stocks have pulled back from this morning's gains, amid the ongoing Russia-Ukraine border crisis, with all three benchmarks looking to extend their losing streaks.

Via Talk Markets

40 Stocks Moving In Wednesday's Mid-Day Session ↗

February 23, 2022

Gainers Tenneco Inc. (NYSE: TEN) shares jumped 94.1% to $19.38 after the company announced it will be acquired by Apollo Funds. Tenneco also reported a Q4 loss of $0.11 per share...

Via Benzinga

Kodiak Stock Pummeled After Attempt To Improve On Regeneron's Blockbuster Backfired ↗

February 23, 2022

Kodiak hoped a less frequent dosing plan would benefit patients with an eye disease.

Via Investor's Business Daily

Mid-Morning Market Update: U.S. Stocks Open Higher; Lowe's Tops Q4 Expectations ↗

February 23, 2022

U.S. stocks opened higher this morning after recording sharp losses on Tuesday. US President Biden late Tuesday announced sanctions on some Russian banks and individuals....

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

February 23, 2022

Gainers Revelation Biosciences (NASDAQ:REVB) stock increased by 29.9% to $2.0 during Wednesday's pre-market session. The market value of their outstanding shares is at...

Via Benzinga

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗

February 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...

Via Benzinga

Why Kodiak Sciences Shares Are Plunging Today ↗

February 23, 2022

Kodiak Sciences Inc (NASDAQ: KOD) has announced topline results from its Phase 2b/3 trial evaluating KSI-301 in treatment-naïve subjects with neovascular (wet) age-...

Via Benzinga

Executives Buy Around $500M Of 4 Stocks ↗

February 18, 2022

US stocks traded lower on Friday after recording sharp losses on Thursday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022 ↗

February 02, 2022

Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.